What's Shaping CVS' Health Care Benefits Arm for the Rest of 2025?

CVS Health's Health Care Benefits segment reported an 8% year-over-year growth in Q1 2025, primarily driven by Medicare strength and improved star ratings, with Aetna nearing target margins despite elevated but stabilizing medical cost trends. The company plans to exit the individual Affordable Care Act (ACA) exchange business in 2026, booking a $448 million reserve for associated 2025 losses, to concentrate on Medicare, commercial, and Medicaid. This strategic focus and an improved Medical Benefit Ratio (87.3% in Q1, 91.3% projected for full-year) are expected to drive the segment's adjusted operating income to approximately $1.91 billion, contributing to CVS shares' 36.1% year-to-date outperformance against the industry.

Analysis

CVS Health's Health Care Benefits segment demonstrated robust performance in Q1 2025, with an 8% year-over-year revenue increase driven primarily by strength in its Medicare business and improved Medicare Advantage star ratings. This growth contributed to significant margin improvement, evidenced by a 310 basis point improvement in the medical benefit ratio (MBR) to 87.3%. Despite this, the company acknowledges that elevated medical cost trends persist, though they are showing initial signs of stabilization, and projects a higher full-year MBR of 91.3%. A key strategic development is the planned exit from the individual Affordable Care Act (ACA) exchange business by 2026 to sharpen focus on the more profitable Medicare, commercial, and Medicaid segments. This transition necessitates a $448 million reserve for expected 2025 losses and will result in a nearly 300,000-member decline in Q2. Despite these headwinds, the segment's adjusted operating income is projected to rise by approximately $400 million to $1.91 billion for the year. This positive operational outlook is reflected in the stock's 36.1% year-to-date gain, starkly outperforming the industry's 10.3% decline, while still trading at a discounted forward P/E ratio of 9.24 versus the industry average of 13.59.

Key Decisions for Investors

• Given the stock's significant outperformance combined with a discounted forward P/E ratio relative to its industry, investors may view the current valuation as an attractive opportunity, supported by bullish analyst estimates.
• Investors should closely monitor the full-year medical benefit ratio projection of 91.3%, as any deviation could signal that elevated medical cost trends are not stabilizing as anticipated, posing a risk to profitability.
• The strategic pivot away from the ACA market to focus on Medicare and commercial lines is a critical catalyst; therefore, tracking progress on Aetna's target margins and the performance of these core segments is essential to validating the long-term thesis.